Aptus Capital Advisors LLC Sells 426 Shares of Sanofi (NASDAQ:SNY)

Aptus Capital Advisors LLC cut its stake in Sanofi (NASDAQ:SNY) by 10.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,792 shares of the company’s stock after selling 426 shares during the quarter. Aptus Capital Advisors LLC’s holdings in Sanofi were worth $219,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Manning & Napier Advisors LLC acquired a new position in shares of Sanofi in the second quarter valued at about $13,725,000. Mount Yale Investment Advisors LLC grew its stake in Sanofi by 44.3% during the first quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock worth $2,027,000 after buying an additional 12,806 shares in the last quarter. GFS Advisors LLC grew its stake in Sanofi by 1,017.9% during the third quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock worth $738,000 after buying an additional 11,655 shares in the last quarter. Atria Investments Inc grew its stake in Sanofi by 31.1% during the first quarter. Atria Investments Inc now owns 98,878 shares of the company’s stock worth $4,805,000 after buying an additional 23,463 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. grew its stake in Sanofi by 15.2% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 116,917 shares of the company’s stock worth $5,673,000 after buying an additional 15,439 shares in the last quarter. 10.04% of the stock is owned by institutional investors.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $47.97 on Friday. The company’s 50-day moving average is $54.65 and its 200 day moving average is $52.22. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The company has a market capitalization of $121.74 billion, a P/E ratio of 24.47, a price-to-earnings-growth ratio of 1.26 and a beta of 0.61. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. The business had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company’s revenue was up 12.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.55 earnings per share. On average, equities research analysts forecast that Sanofi will post 4.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Argus increased their price objective on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Finally, StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.